XJPX
3593
Market cap884mUSD
May 14, Last price
6,660.00JPY
Name
Hogy Medical Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Hogy Medical Co.,Ltd., along with its affiliated entities, operates within Japan, specializing in a diverse array of medical products. Their offerings encompass medical-grade and non-woven textiles, comprehensive surgical kits, and various other healthcare solutions. The company provides specialized kit solutions designed for surgical procedures, including integrated kits that cover the entire perioperative phase (before, during, and after surgery). Its non-woven product line features items like protective gowns, personal protective equipment (PPE), wearable medical garments, surgical drapes, pre-packaged sterile items, covers for instrument tables, and wraps. A notable non-woven innovation is Tigalyer, distinguished by its liquid barrier and waterproofing capabilities. Furthermore, Hogy Medical supplies a range of sterilization products, such as various hybrid Mekkin bags and autoclave forceps stands. To ensure sterilization efficacy, they offer detection cards like Mekkin cards for autoclave processes and ethylene oxide gas cards for EO gas sterilization, alongside indicator tapes for autoclave use. Beyond physical products, the company delivers advanced management systems, including Opera Master for surgical workflow optimization, a system for managing medical electronic (ME) equipment operations, and an automated drug reading and management system for narcotics and poisons, utilizing radio frequency identification (RFID) technology. Additional medical devices include endoscope holders and Securea, a specialized polyurethane sponge engineered for endoscopic surgical applications. Founded in 1961, the company, originally known as Hogy Co., Ltd., adopted its current name, Hogy Medical Co.,Ltd., in 1987. Its corporate headquarters are located in Tokyo, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||